Where Nordic Science Meets Global Capital: A Conversation with Ted Fjällman
By Helena Strigård, CEO of Ventures Accelerated
April 23, 2026
In a conversation between Helena Strigård, CEO of Ventures Accelerated, and Ted Fjällman, CEO of Flerie, a Swedish life-science investment firm, Fjällman shared his perspective on how European life science companies can attract global capital and why combining the strengths from different investment cultures may be the key to scaling innovation.
The discussion explored the evolving landscape for life science funding in Europe, the role of Stockholm within global capital markets, and how investors and founders can navigate today’s tougher financing climate.
Ted Fjällman, CEO of Flerie
Taking the Best from Two Worlds
A recurring theme in the conversation was the contrast between Nordic and American investment cultures.
According to Fjällman, Nordic founders and investors tend to emphasise scientific rigour, careful analysis, and modest communication. In the United States, the tone is often opposite: bold storytelling, strong confidence, and a clear focus on market potential.
Fjällman believes the most successful collaborations happen when the strengths of both cultures come together. Nordic life science ecosystems bring deep scientific expertise and disciplined execution, while American investors contribute ambition, scale, and access to larger capital markets.
By bridging these cultural approaches, companies and investors can unlock opportunities that neither side could reach alone.
Catalysing Larger Investment Rounds
Fjällman also highlighted an important dynamic within venture investing: there are far more followers than leaders.
Many investors prefer to join a round once someone else has taken the lead and validated the opportunity. As a result, companies often look for an anchor investor or a strong syndicate to help initiate momentum.
Part of this caution, Fjällman explains, comes from how many investment firms are structured. Decision-makers are typically partners operating much like employees within larger organisations, which can make them reluctant to take the first and most visible risk if a deal fails.
Flerie can for the right opportunity fill that important role as a lead investor and actively be the catalyst for others to join a syndicate. Fjällman said that when Flerie invests this is often followed with 2-3 times as much deployment by others into that same company.
By committing early and helping structure funding rounds, Flerie enables promising companies to raise significantly larger amounts of capital than they might otherwise secure.
Trust Built on Rigorous Due Diligence
Another factor that attracts co-investors is Flerie’s reputation for thorough and independent due diligence.
In several cases, the firm has identified and evaluated companies independently before bringing additional investors into a round. According to Fjällman, this level of analysis builds trust across the investment community.
“When we commit to a company, others know the opportunity has been carefully vetted,” he explains.
This credibility allows Flerie to work alongside investors from multiple regions, including the United States, Europe, and Asia, while helping European startups connect with international capital.
Building a Stronger Ecosystem Through Collaboration
For Fjällman, the future of European life science innovation depends on collaboration across borders, capital sources, and cultures.
When Nordic scientific depth meets the scale and ambition of global investors, and when experienced investors help catalyse larger financing rounds, more promising innovations can move from the lab to the market.
And ultimately, that is what the ecosystem needs most.